Pancreatic Cancer Research

ResearcherPaz PharmaceuticalsActive in the last 2 years

Haiyong Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9031-9880; OpenAlex author ID A5037894273; NIH RePORTER profile ID 8146160. Sources: OpenAlex.

Their work

Papers
43 (first author 2, last author 13)
Trials
0
Grants
4
Labs led
1
Collaborators
127
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper, 1 grant · 2017: 4 papers, 1 grant · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 8 papers, 1 grant · 2023: 5 papers · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers, 1 grant

Papers 43

  1. Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [… Co-author DOI 10.1016/j.redox.2026.104395↗
  2. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  3. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  4. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.36401/jipo-25-20↗
  5. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  6. A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection. Co-author DOI 10.1021/acsnano.5c10607↗
  7. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-025-03167-2↗
  8. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  9. Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/ph17070911↗
  10. Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.09.008↗
  11. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  12. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
  13. Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer. Last author DOI 10.1038/s41598-023-44211-6↗
  14. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines11010119↗
  15. Effect of acoustic cluster therapy (ACT®) combined with chemotherapy in a patient-derived xenograft mouse model of pancreatic cancer. Last author DOI 10.1016/j.jconrel.2022.11.016↗
  16. Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Co-author DOI 10.1016/j.medj.2021.12.008↗
  17. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Co-author DOI 10.1038/s41417-021-00350-4↗
  18. Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β2 adrenergic agonist. Co-author DOI 10.1038/s41598-022-07600-x↗
  19. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  20. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Co-author DOI 10.1158/0008-5472.can-21-4222↗
  21. Increasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR). Co-author DOI 10.3390/ijms24010577↗
  22. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ph15101199↗
  23. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer. Co-author DOI 10.1002/mc.23339↗
  24. Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. Co-author DOI 10.1002/onco.13645↗
  25. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Last author DOI 10.1038/s41389-020-00285-9↗
  26. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Last author DOI 10.1186/s13073-020-00776-9↗
  27. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.cell.2019.03.010↗
  28. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Co-author DOI 10.18632/oncotarget.23321↗
  29. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Co-author DOI 10.7150/thno.26650↗
  30. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.209↗
  31. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Co-author DOI 10.1093/carcin/bgx065↗
  32. Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. Last author DOI 10.1371/journal.pone.0183871↗
  33. Preparation and Metabolic Assay of 3-dimensional Spheroid Co-cultures of Pancreatic Cancer Cells and Fibroblasts. Last author DOI 10.3791/56081↗
  34. Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells. Last author DOI 10.1371/journal.pone.0165586↗
  35. Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. First author DOI 10.1097/ppo.0000000000000140↗
  36. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-14-1051↗
  37. SnapShot: pancreatic cancer. Co-author DOI 10.1016/j.ccr.2013.03.008↗
  38. Tumor-stromal interactions in pancreatic cancer. First author DOI 10.1615/critrevoncog.v18.i1-2.80↗
  39. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Last author DOI 10.1016/j.bcp.2011.11.005↗
  40. Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0032783↗
  41. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. Co-author DOI 10.1371/journal.pone.0043192↗
  42. Perineural invasion and associated pain in pancreatic cancer. Last author DOI 10.1038/nrc3131↗
  43. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Last author DOI 10.1158/1078-0432.ccr-10-2214↗

Grants 4

  1. Targeting cellular senescense in pancreatic cancer R21CA299593↗
  2. Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer R41CA275625↗
  3. Targeting Stromal Collagen in Pancreatic Cancer R01CA169281↗
  4. Targeting PHD2 in Pancreatic Cancer R21CA191923↗

Closest collaborators

The 25 strongest of 127 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 34 shared papers, 1 shared grant, 2011–2026 · strength 4.32
  2. Erkut Hasan Borazanci · 10 shared papers, 2020–2026 · strength 1.82
  3. Derek Cridebring · 9 shared papers, 2020–2026 · strength 1.53
  4. Ajay Goel · 8 shared papers, 2017–2026 · strength 1.41
  5. Gayle Jameson · 7 shared papers, 2017–2026 · strength 1.26
  6. Michael T. Barrett · 7 shared papers, 2012–2026 · strength 0.92
  7. Serina Ng · 7 shared papers, 2017–2023 · strength 0.91
  8. Ronald M. Evans · 6 shared papers, 2020–2025 · strength 0.87
  9. Carlos Roberto Becerra · 4 shared papers, 2022–2026 · strength 0.70
  10. Irving Wainer · 1 shared grant, 2022 · strength 0.66
  11. Caiming Xu · 3 shared papers, 2022–2024 · strength 0.61
  12. Cristina Fillat · 3 shared papers, 2022–2024 · strength 0.61
  13. Silvia Pascual-Sabater · 3 shared papers, 2022–2024 · strength 0.61
  14. Mitsuro Kanda · 3 shared papers, 2025–2026 · strength 0.61
  15. Vincent M. Chung · 3 shared papers, 2025–2026 · strength 0.60
  16. David J. Propper · 3 shared papers, 2023–2026 · strength 0.56
  17. John S. Bolton · 3 shared papers, 2022–2026 · strength 0.50
  18. Eunsung Jun · 3 shared papers, 2022–2026 · strength 0.50
  19. Joon Oh Park · 3 shared papers, 2020–2026 · strength 0.49
  20. Caiming Xu · 2 shared papers, 2026 · strength 0.39
  21. Laleh Golkar Melstrom · 2 shared papers, 2026 · strength 0.39
  22. Giulia Martina Cavestro · 2 shared papers, 2026 · strength 0.39
  23. Douglas B. Evans · 2 shared papers, 2026 · strength 0.39
  24. David L. Bartlett · 2 shared papers, 2026 · strength 0.39
  25. Alessandro Mannucci · 2 shared papers, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.